POTELIGEO had a median time to response of about 1 month in blood^1,a-g

• ^aTime to response was measured based on a post hoc analysis; a finding from the post hoc analysis cannot be used to demonstrate differences between treatments and may not be applicable to all patients initiating POTELIGEO.
• ^bResponse was defined by international response criteria for Mycosis Fungoides and Sézary Syndrome.²
• ^cResponses in skin and blood must have persisted for ≥4 weeks to be confirmed and were evaluated every 4 weeks during treatment.^3,4
• ^dResponses in lymph nodes were evaluated at 4 weeks, then every 8 weeks for the first year, and every 16 weeks thereafter.¹
• ^eResponse in skin defined as ≥50% clearance of skin disease without new tumors, evaluated using the modified Severity Weighted Assessment Tool (mSWAT).⁴
• ^fResponse in blood defined as >50% decrease in high blood tumor burden (B2), assessed by central flow cytometry.⁴
• ^gResponse in lymph nodes defined as cumulative reduction ≥50% of measurable disease of each abnormal lymph node and no new abnormal lymph nodes, evaluated by computed tomography (CT) scans.⁴

In a post hoc analysis, POTELIGEO demonstrated a longer TTNT in patients with Mycosis Fungoides and Sézary Syndrome vs vorinostat^5,h

• TTNT was defined as time to any significant therapy (systemic treatment, total skin radiation, or psoralen-UVA therapy)⁵
• POTELIGEO also demonstrated significantly longer TTNT vs vorinostat across blood classifications⁶

BLOOD CLASSIFICATION

• 

• <15%
  CD4+CD26- or CD4+CD7-cells by flow cytometry

• 
• ≥15%
  CD4+CD26- or CD4+CD7- cells by flow cytometry

• 

• ≥1000/μL Sézary cells with positive clone
  or 1 of the following:

  • CD4:CD8 ratio ≥10,
  • 40% CD4+CD7- cells, or
  • ≥30% CD4+CD26- cells

• ^hFindings from the post hoc analysis cannot be used to demonstrate differences between treatments and may not be applicable to all patients initiating POTELIGEO.
• ITT=intent-to-treat; TTNT=time to next treatment; UVA=ultraviolet A

POTELIGEO was evaluated in the largest randomized, open-label, phase 3 trial of a systemic therapy for patients with Mycosis Fungoides and Sézary Syndrome^1,3,7

Expand for
Study Design

372 patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS) were evaluated across Stage IB-IV for progression-free survival (PFS) as well as overall response rate (ORR) and duration of response (DoR) in multiple disease compartments (skin, blood, lymph nodes, viscera).

MAVORIC

Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL

The MAVORIC trial included a broad range of patients^1,3,8

BLOOD CLASSIFICATION^4,6

• (n=64)

• <15%
  CD4+CD26- or CD4+CD7-cells by flow cytometry

• (n=31)
• ≥15%
  CD4+CD26- or CD4+CD7- cells by flow cytometry

• (n=91)

• ≥1000/μL Sézary cells with positive clone
  or 1 of the following:

  • CD4:CD8 ratio ≥10,
  • 40% CD4+CD7- cells, or
  • ≥30% CD4+CD26- cells

Patient characteristics3,8
Age (years)
Age (years)	Median, 64	Min, 25	Max, 101
Sex
Sex	Males, 58%	Females, 42%
Race
Race	White, 70%	African American, 13%	Asian, 7%	Other, 10% (Not reported)
Prior systemic therapies
Prior systemic therapies	Median, 3	Min, 0	Max, 18

Key exclusion criteria⁴

• Large cell transformation at study entry
• Active autoimmune diseases
• CNS metastasis

• Active infection requiring therapy
• Medical conditions requiring initiation of systemic corticosteroids or other immunosuppressive medication

CNS=central nervous system; CTCL=cutaneous T-cell lymphoma; PO=by mouth; R/R=relapsed or refractory